Bioscience

Abraxis BioScience, Inc. Tops Taxol in Cancer Study

March 18, 2010

By Flinn Foundation

[Source: Transworld News] – Abraxis BioScience Inc. announced that its chemotherapeutic compound ABRAXANE® has demonstrated a significant improvement in overall response rate in the treatment of the most common form of lung cancer when compared to Taxol®, based upon independent radiologist review.

 

The study was a randomized registrational Phase 3 clinical trial comparing ABRAXANE (protein-bound paclitaxel) with Taxol (paclitaxel) injection, both in combination with carboplatin, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). One of the largest NSCLC clinical studies ever conducted, it involved over 1,000 patients, at 102 different sites around the world.

 

For more information: Abraxis BioScience, Inc. (ABII) Tops Taxol in Cancer Study